Dalotuzumab
- Generic Name
- Dalotuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1005389-60-5
- Unique Ingredient Identifier
- 6YI1L648RH
- Background
Dalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2020-05-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT01609231
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT01605396
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
- First Posted Date
- 2011-09-09
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 21
- Registration Number
- NCT01431547
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 47
- Registration Number
- NCT01243762
A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 115
- Registration Number
- NCT01234857
The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 63
- Registration Number
- NCT01220570
FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2015-02-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT00903006
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 81
- Registration Number
- NCT00769483
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT00701103
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath